BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olivera-Martinez M, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Hepatorenal syndrome: are we missing some prognostic factors? Dig Dis Sci. 2012;57:210-214. [PMID: 21850494 DOI: 10.1007/s10620-011-1861-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20(33): 11684-11699 [PMID: 25206273 DOI: 10.3748/wjg.v20.i33.11684] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 53] [Article Influence: 9.1] [Reference Citation Analysis]
2 Udgirkar S, Rathi P, Sonthalia N, Chandnani S, Contractor Q, Thanage R, Jain S. Urinary neutrophil gelatinase-associated lipocalin determines short-term mortality and type of acute kidney injury in cirrhosis.JGH Open. 2020;4:970-977. [PMID: 33102772 DOI: 10.1002/jgh3.12377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sheng XY, Lin FY, Wu J, Cao HC. Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study. World J Gastroenterol 2021; 27(20): 2615-2629 [PMID: 34092979 DOI: 10.3748/wjg.v27.i20.2615] [Reference Citation Analysis]
4 Kasztelan-Szczerbinska B, Slomka M, Celinski K, Szczerbinski M. Alkaline phosphatase: the next independent predictor of the poor 90-day outcome in alcoholic hepatitis. Biomed Res Int. 2013;2013:614081. [PMID: 24151614 DOI: 10.1155/2013/614081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
5 Low G, Alexander GJ, Lomas DJ. Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract 2015;2015:207012. [PMID: 25649410 DOI: 10.1155/2015/207012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
6 Gungor G, Ataseven H, Demir A, Solak Y, Gaipov A, Biyik M, Ozturk B, Polat I, Kiyici A, Cakir OO. Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study. Liver Int. 2014;34:49-57. [PMID: 23799980 DOI: 10.1111/liv.12232] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
7 Hung TH, Tsai CC, Tseng KC, Tseng C-, Hsieh YH, Tsai CC, Lee HF. High Mortality of Cirrhotic Patients With End-Stage Renal Disease. Medicine (Baltimore) 2016;95:e3057. [PMID: 26962834 DOI: 10.1097/MD.0000000000003057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
8 Erly B, Carey WD, Kapoor B, McKinney JM, Tam M, Wang W. Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options. Semin Intervent Radiol. 2015;32:445-454. [PMID: 26622108 DOI: 10.1055/s-0035-1564794] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hiremath SB, Srinivas LD. Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis. Indian J Pharmacol 2013;45:54-60. [PMID: 23543867 DOI: 10.4103/0253-7613.106436] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
10 Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline vs terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol. 2018;37:424-429. [PMID: 30178092 DOI: 10.1007/s12664-018-0876-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]